Autres langues Edgewise Therapeutics, Inc.

Actions

EWTX

US28036F1057

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 29/04/2024			Varia. 5j.	Varia. 1 janv.
17,05 ^USD	+5,44 %		+13,06 %	+55,85 %

23/04	EDGEWISE THERAPEUTICS, INC. : RBC Capital Markets optimiste sur le dossier	ZM
15/04	Edgewise Therapeutics, Inc. Edgewise Therapeutics Inc. annonce des résultats positifs à deux ans de l'essai ouvert Arch sur Sevasemten (EDG-5506) chez des adultes atteints de dystrophie musculaire de Becker (Becker)	CI

Autres langues

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Edgewise Receives European Medicines Agency Orphan Drug Designations for Sevasemten for the Treatment of Becker and Duchenne Muscular Dystrophies	24/04
Edgewise Therapeutics Secures Orphan Drug Designations for Sevasemten in EU	23/04
Edgewise Receives European Medicines Agency (EMA) Orphan Drug Designations for Sevasemten (EDG-5506) for the Treatment of Becker and Duchenne Muscular Dystrophies	23/04
Edgewise Therapeutics : EDG-5506 ARCH 2 YR Topline Results	19/04
Sector Update: Health Care Stocks Mixed Premarket Tuesday	16/04
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten in Adults with Becker Muscular Dystrophy	16/04
Edgewise Therapeutics : EDG-5506 ARCH 2 YR Topline Results April 2024	16/04
Edgewise Therapeutics Reports 'Positive' Two-Year Results From Becker Muscular Dystrophy Trial	15/04
Edgewise Therapeutics Announces Positive Two-Year Topline Results from the ARCH Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy (Becker)	15/04
Edgewise Therapeutics, Inc. Announces Positive Two-Year Topline Results from the Arch Open Label Trial of Sevasemten (EDG-5506) in Adults with Becker Muscular Dystrophy	15/04
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session	28/03
Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session	28/03
Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024	27/03
Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024	05/03
Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference	28/02
Edgewise Therapeutics Full Year 2023 Net Loss Widens	22/02
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights	22/02
Edgewise Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	22/02
Edgewise Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	22/02
Edgewise Receives U.S. FDA Fast Track Designation for EDG-5506 for the Treatment of Duchenne Muscular Dystrophy	14/02

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Autres langues Edgewise Therapeutics, Inc.

Actions

EWTX

US28036F1057

Autres langues

Filtres